<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00098046</url>
  </required_header>
  <id_info>
    <org_study_id>CFAM810B2304</org_study_id>
    <nct_id>NCT00098046</nct_id>
  </id_info>
  <brief_title>Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection</brief_title>
  <official_title>Pharmacokinetics and Safety of Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Varicella zoster virus causes chickenpox in children and shingles in adults. Chickenpox is
      usually a self-limiting illness characterized by fever and a rash. Serious complications can
      include secondary bacterial infections, pneumonia, and encephalitis. Anti-viral treatment is
      not a standard of care in immunocompetent children, but is recommended whenever a risk of
      complication exists. This study will evaluate the safety and blood levels of a new
      formulation of famciclovir in children 1-12 years of age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Step A: Single-dose safety and pharmacokinetics</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Step B: Safety and tolerability of pediatric formulation administered 3 times daily over 7 days</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Steps A &amp; B: Acceptability of pediatric formulation by patients</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Chickenpox</condition>
  <condition>Herpes Zoster</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>famciclovir</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female children 1-12 years of age

          -  Clinical or laboratory evidence of varicella zoster infection

          -  Patients suspected of having varicella zoster infection

        Exclusion Criteria:

          -  Patients unable to swallow

          -  Concomitant use of probenecid

          -  Positive pregnancy

        Additional protocol-defined inclusion/exclusion criterial may apply. For detailed
        information on eligibility, please contact the study center nearest to you (see below), or
        call the following number 1-862-778-3544 or 1-434-951-3228
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>San Jose</city>
        <country>Costa Rica</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Cuidad de Guatemala</city>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>Ciudad de Panama</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigational Site</name>
      <address>
        <city>David, Chiriqui</city>
        <country>Panama</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Costa Rica</country>
    <country>Guatemala</country>
    <country>Panama</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2004</study_first_submitted>
  <study_first_submitted_qc>December 2, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2004</study_first_posted>
  <last_update_submitted>September 25, 2007</last_update_submitted>
  <last_update_submitted_qc>September 25, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2007</last_update_posted>
  <keyword>chickenpox</keyword>
  <keyword>herpes zoster</keyword>
  <keyword>children</keyword>
  <keyword>Famvir</keyword>
  <keyword>varicella zoster virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Famciclovir</mesh_term>
    <mesh_term>2-Aminopurine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

